PE20171380A1 - Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada - Google Patents

Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada

Info

Publication number
PE20171380A1
PE20171380A1 PE2017000987A PE2017000987A PE20171380A1 PE 20171380 A1 PE20171380 A1 PE 20171380A1 PE 2017000987 A PE2017000987 A PE 2017000987A PE 2017000987 A PE2017000987 A PE 2017000987A PE 20171380 A1 PE20171380 A1 PE 20171380A1
Authority
PE
Peru
Prior art keywords
polypeptide
ctp
hgh
growth hormone
polypeptides
Prior art date
Application number
PE2017000987A
Other languages
English (en)
Inventor
Oren Hershkovitz
Laura Moschcovich
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of PE20171380A1 publication Critical patent/PE20171380A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Human Resources & Organizations (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Biotechnology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Economics (AREA)
  • Development Economics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Educational Administration (AREA)
  • Theoretical Computer Science (AREA)
  • Game Theory and Decision Science (AREA)
  • General Business, Economics & Management (AREA)
  • Marketing (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Quality & Reliability (AREA)
  • Tourism & Hospitality (AREA)
  • Operations Research (AREA)
  • Finance (AREA)

Abstract

Se refiere a un polipeptido de hormona de crecimiento humana (hGH) modificado con un peptido terminal carboxi de la hormona gonadotropina corionica humana (CTP), donde dicho polipeptido comprende: a) dos CTP unidos al extremo carboxi de la hGH; y b) un CTP unido al extremo amino de la hGH. Dicho polipeptido comprende una secuencia de aminoacido SEC ID NO:7 y a su vez comprende glicosilaciones entre 13 y 18 sitios de glicosilacion unidos a O. Tambien se refiere a una composicion farmaceutica y a un procedimiento de obtencion de dicho polipeptido. Dicho polipeptido es util en el aumento y mantenimiento del nivel del factor de crecimiento similar a la insulina (IGF-1), crecimiento oseo, entre otros
PE2017000987A 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada PE20171380A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090116P 2014-12-10 2014-12-10
US201462090104P 2014-12-10 2014-12-10
US201462090124P 2014-12-10 2014-12-10

Publications (1)

Publication Number Publication Date
PE20171380A1 true PE20171380A1 (es) 2017-09-15

Family

ID=56106835

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000987A PE20171380A1 (es) 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada

Country Status (22)

Country Link
US (3) US20180111974A1 (es)
EP (4) EP3240564A4 (es)
KR (3) KR102164352B1 (es)
CN (1) CN107438623B (es)
AU (2) AU2015358890B2 (es)
CO (1) CO2017006870A2 (es)
EA (1) EA201791275A1 (es)
ES (1) ES2943359T3 (es)
HK (2) HK1243444A1 (es)
HR (1) HRP20230405T8 (es)
IL (2) IL252778B (es)
MX (2) MX2017007634A (es)
NZ (1) NZ733113A (es)
PE (1) PE20171380A1 (es)
PH (1) PH12017501089A1 (es)
PL (1) PL3230309T3 (es)
RU (2) RU2743295C2 (es)
SG (1) SG11201704706RA (es)
SI (1) SI3230309T1 (es)
TW (2) TWI746427B (es)
WO (2) WO2016092549A1 (es)
ZA (1) ZA201704595B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (zh) 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201808988A (zh) * 2016-07-11 2018-03-16 歐科生物製品有限公司 長效型凝血因子及其生產方法
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2021005604A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
BR112023018980A2 (pt) * 2021-03-19 2023-12-05 Opko Biologics Ltd Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
ATE109507T1 (de) * 1989-04-28 1994-08-15 Miles Inc Grossfermenter-inokulation mit gefrorenen zellen.
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
DE69422169D1 (de) * 1993-04-20 2000-01-20 Univ St Louis Modifizierte proteine und peptide enthaltende pharmazeutische mittel
WO1995035116A1 (en) * 1994-06-17 1995-12-28 Applied Research Systems Hgh containing pharmaceutical compositions
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN1847265A (zh) * 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
BR122021004014B1 (pt) 2012-02-14 2022-12-27 Opko Biologics Ltd Métodos para melhorar a área sob a curva (auc), reduzir a frequência da dosagem e reduzir a taxa de liberação de um fator de coagulação
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
BR112015011583B1 (pt) * 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
EP2981282B1 (en) * 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
CN107438623B (zh) 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
US10960058B2 (en) * 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same

Also Published As

Publication number Publication date
HRP20230405T1 (hr) 2023-09-01
TWI746427B (zh) 2021-11-21
EP3230309A1 (en) 2017-10-18
MX2017007634A (es) 2017-08-28
AU2019203609B2 (en) 2021-02-25
US20180111974A1 (en) 2018-04-26
US20210371487A1 (en) 2021-12-02
IL252788B (en) 2021-09-30
RU2017123789A (ru) 2019-01-10
SG11201704706RA (en) 2017-07-28
HK1243444A1 (zh) 2018-07-13
KR102527180B1 (ko) 2023-04-27
ES2943359T3 (es) 2023-06-12
HK1246322A1 (zh) 2018-09-07
CN107438623A (zh) 2017-12-05
EP3230309B1 (en) 2023-03-29
US20160168588A1 (en) 2016-06-16
KR20220058564A (ko) 2022-05-09
WO2016092550A3 (en) 2016-08-04
WO2016092549A1 (en) 2016-06-16
RU2021103436A (ru) 2021-02-25
EP4253407A3 (en) 2023-12-06
HRP20230405T8 (hr) 2023-09-29
EP4253407A2 (en) 2023-10-04
AU2015358890B2 (en) 2019-06-13
RU2743295C2 (ru) 2021-02-16
MX2017007635A (es) 2017-09-11
KR20170086664A (ko) 2017-07-26
TW201638105A (zh) 2016-11-01
IL252778A0 (en) 2017-08-31
KR20200118505A (ko) 2020-10-15
IL252778B (en) 2021-09-30
PL3230309T3 (pl) 2023-08-28
AU2015358890A1 (en) 2017-07-20
PH12017501089A1 (en) 2017-10-18
AU2019203609A1 (en) 2019-06-13
BR112017012498A2 (pt) 2018-07-31
CN107438623B (zh) 2023-07-14
RU2017123789A3 (es) 2019-01-10
KR102164352B1 (ko) 2020-10-13
NZ733113A (en) 2020-09-25
IL252788A0 (en) 2017-08-31
EP4212546A1 (en) 2023-07-19
TW202231657A (zh) 2022-08-16
WO2016092550A2 (en) 2016-06-16
SI3230309T1 (sl) 2023-08-31
EP3240564A2 (en) 2017-11-08
EP3240564A4 (en) 2018-05-30
CO2017006870A2 (es) 2018-01-05
EA201791275A1 (ru) 2017-12-29
ZA201704595B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
CO7200249A2 (es) Variantes de oxintomodulina de acción prolongada y métodos de producción de las mismas
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
DOP2009000194A (es) Glucagon/co-agonistas receptores de glp-1
TR201821186T4 (tr) Uzun süre etkili büyüme hormonu ve bunun üretim metotları.
PA8830501A1 (es) Co-agonistas del receptor de glucagon/glp-1
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
PE20140186A1 (es) Analogos de glucagon que presentan actividad de receptor de gip
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
AR096162A1 (es) Péptidos terapéuticos
CL2020002574A1 (es) Análogos novedosos de glp-1
PE20121033A1 (es) Produccion recombinante de peptidos
MX2019000708A (es) Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
WO2016203482A3 (en) Long-acting coagulation factors and methods of producing same
JP2016510728A5 (es)
RU2017101667A (ru) Фармацевтические композиции
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE